Thomas Stuart Matthews

Address:

6400 Rock Service Sta Rd, Raleigh, NC 27603

VIN:

4A3AK24FX9E013019

Make:

MITSUBISHI

Model:

ECLIPSE

Year:

2009

US Patent:

6440656, Aug 27, 2002

Filed:

Jun 7, 1994

Appl. No.:

08/255208

Inventors:

Dani Paul Bolognesi - Durham NC
Thomas James Matthews - Durham NC
Carl T. Wild - Durham NC
Shawn OLin Barney - Cary NC
Dennis Michael Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

C12Q 170

US Classification:

435 5, 435 71, 530300, 530324, 530325, 530326, 4242111

Abstract:

Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C. A. S. T. ) that detects related structural motifs (e. g. , ALLMOTI5, 107Ã178Ã4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion.

US Patent:

6479055, Nov 12, 2002

Filed:

Jun 6, 1995

Appl. No.:

08/470896

Inventors:

Dani Paul Bolognesi - Durham NC
Thomas James Matthews - Durham NC
Carl T. Wild - Durham NC
Shawn OLin Barney - Cary NC
Dennis Michael Lambert - Cary NC
Stephen Robert Petteway - Cary NC
Alphonse J. Langlois - Durham NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 39145

US Classification:

4242111, 4241861, 530324

Abstract:

The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus (âRSVâ) transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1 transmembrane protein (TM) gp41.

US Patent:

6573078, Jun 3, 2003

Filed:

Jun 2, 1995

Appl. No.:

08/464003

Inventors:

Carl T. Wild - Durham NC
Thomas J. Matthews - Durham NC
Dani P. Bolognesi - Durham NC

Assignee:

Duke University - Durham NC

International Classification:

C12N 508

US Classification:

4352351, 4241881, 4242081, 530324, 530806, 514 12

Abstract:

This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.

US Patent:

6824783, Nov 30, 2004

Filed:

Jun 7, 1995

Appl. No.:

08/487266

Inventors:

Dani Paul Bolognesi - Durham NC
Thomas James Matthews - Durham NC
Carl T. Wild - Durham NC

Assignee:

Duke University - Durham NC

International Classification:

A61K 3921

US Classification:

4241881, 4242081, 435 5, 530360

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1 gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

US Patent:

7122190, Oct 17, 2006

Filed:

Oct 9, 2002

Appl. No.:

10/267748

Inventors:

Dani Paul Bolognesi - Durham NC, US
Thomas James Matthews - Durham NC, US
Carl T. Wild - Durham NC, US
Shawn O'Lin Barney - Cary NC, US
Dennis Michael Lambert - Cary NC, US
Stephen Robert Petteway - Cary NC, US
Alphonse J. Langlois - Durham NC, US

Assignee:

Duke University - Durham NC

International Classification:

A61K 39/21

US Classification:

4241881, 4241921, 4242081

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

US Patent:

7273614, Sep 25, 2007

Filed:

Oct 9, 2002

Appl. No.:

10/267682

Inventors:

Dani Paul Bolognesi - Durham NC, US
Thomas James Matthews - Durham NC, US
Carl T. Wild - Durham NC, US

Assignee:

Duke University - Durham NC

International Classification:

A61K 39/21

US Classification:

4241881, 4242081

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

US Patent:

20030181382, Sep 25, 2003

Filed:

Apr 15, 2003

Appl. No.:

10/414192

Inventors:

Carl Wild - Durham NC, US
Thomas Matthews - Durham NC, US
Dani Bolognesi - Durham NC, US

Assignee:

Duke University

International Classification:

A61K038/16
C07K014/16

US Classification:

514/012000, 530/395000

Abstract:

This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.

US Patent:

20070037141, Feb 15, 2007

Filed:

Dec 17, 2003

Appl. No.:

10/739355

Inventors:

Darii Bolognesi - Durham NC, US
Thomas Matthews - Durham NC, US
Carl Wild - Durham NC, US
Shawn Barney - Cary NC, US
Dennis Lambert - Cary NC, US
Stephen Petteway - Cary NC, US
Alphonse Langlois - Durham NC, US

International Classification:

C12Q 1/70

US Classification:

435005000, 530350000, 530324000

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.